A4978
阿屈膦酸盐 钠 三水合物
≥97% (NMR), bone resorption inhibitor, powder
别名:
4-氨基-1-羟基-1-膦酸丁酯，单钠, MK-217
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C4H12NaNO7P2 · 3 H2O
化学文摘社编号:
分子量:
325.12
UNSPSC Code:
41106300
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
阿屈膦酸盐 钠 三水合物, ≥97% (NMR), powder
Quality Level
assay
≥97% (NMR)
form
powder
color
white
solubility
water, double-distilled: 10 mg/mL
storage temp.
−20°C
SMILES string
[Na+].[H]O[H].[H]O[H].[H]O[H].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O
InChI
1S/C4H13NO7P2.Na.3H2O/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;;;;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);;3*1H2/q;+1;;;/p-1
InChI key
DCSBSVSZJRSITC-UHFFFAOYSA-M
Gene Information
human ... FDPS(2224)
Application
阿仑膦酸钠三水合物已被用于：钛植入物的磷酸钙纳米颗粒（nCaP）二膦酸盐（BP）涂层并用于分析其成骨能力 从老年骨质疏松症患者和健康人群中分离的人骨髓基质细胞（hBMSC）的成骨分化 处理成骨细胞祖细胞和成骨细胞并通过传统测定和简单的数字图象分析研究其对成骨细胞行为的影响
Biochem/physiol Actions
阿仑膦酸钠三水合物是一种骨吸收抑制剂；法尼基二磷酸合成酶抑制剂 (IC 50 = 460 nM)；CD45 蛋白酪氨酸磷酸酶抑制剂。
阿伦膦酸盐是一种含氮二膦酸盐，可阻断甲羟戊酸途径 并限制破骨功能和活性。阿仑膦酸钠三水合物是一种骨吸收抑制剂、法尼基二磷酸合成酶抑制剂和 CD45 蛋白酪氨酸磷酸酶抑制剂。
Preparation Note
重溶后，建议在-20°C下分装冻存。储备液在-20°C条件下可稳定保存6个月。
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
Robert Josse et al.
Current medical research and opinion, 29(3), 205-216 (2013-01-10)
According to the 2010 Osteoporosis Canada Clinical Practice Guidelines, denosumab is a first-line option for the pharmacological management of postmenopausal osteoporosis (PMO), along with several therapeutics that may be more familiar to family practice doctors: bisphosphonates, raloxifene, teriparatide, and hormone
Mattias Ulmner et al.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 72(1), 76-82 (2013-09-03)
To estimate the incidence of bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) associated with the use of oral BPs and osteonecrosis of the jaw (ONJ) not associated with current or previous medication with a BP or radiotherapy to the head
Wei-Yih Chiu et al.
The Journal of clinical endocrinology and metabolism, 98(4), E723-E726 (2013-03-09)
Bisphosphonates effectively increase bone mineral density and reduce fracture risk in patients with osteoporosis, but there are concerns about osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFFs) in the long-term users. So far both complications have not been
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| A4978-100MG | 04061833375297 |